BACKGROUND: The Step Study found that men who had sex with men (MSM) who received anadenovirus type 5 (Ad5) vector-based vaccine and were uncircumcised or had prior Ad5 immunity, had a higher HIV incidence than MSM who received placebo. We investigated whether differences in HIV exposure, measured by reported sexual risk behaviors, may explain the increased risk. METHODS: Among 1764 MSM in the trial, 726 were uncircumcised, 994 had prior Ad5 immunity, and 563 were both uncircumcised and had prior Ad5 immunity. Analyses compared sexual risk behaviors and perceived treatment assignment among vaccine and placebo recipients, determined risk factors for HIV acquisition, and examined the role of insertive anal intercourse in HIV risk among uncircumcised men. RESULTS:Few sexual risk behaviors were significantly higher in vaccine versus placebo recipients at baseline or during follow-up. Among uncircumcised men, vaccine recipients at baseline were more likely to report unprotected insertive anal intercourse with HIV-negative partners (24.9% vs. 18.1%; P = 0.03). Among uncircumcised men who had prior Ad5 immunity, vaccine recipients were more likely to report unprotected insertive anal intercourse with partners of unknown HIV status (46.0% vs. 37.8%; P = 0.05). Vaccine recipients remained at higher risk of HIV infection compared with placebo recipients (hazard ratio = 2.8; 95% confidence interval, 1.2-6.8) controlling for potential confounders. CONCLUSIONS: These analyses do not support a behavioral explanation for the increased HIV infection rates observed among uncircumcised men in the Step Study. Identifying biologic mechanisms to explain the increased risk is a priority .
RCT Entities:
BACKGROUND: The Step Study found that men who had sex with men (MSM) who received an adenovirus type 5 (Ad5) vector-based vaccine and were uncircumcised or had prior Ad5 immunity, had a higher HIV incidence than MSM who received placebo. We investigated whether differences in HIV exposure, measured by reported sexual risk behaviors, may explain the increased risk. METHODS: Among 1764 MSM in the trial, 726 were uncircumcised, 994 had prior Ad5 immunity, and 563 were both uncircumcised and had prior Ad5 immunity. Analyses compared sexual risk behaviors and perceived treatment assignment among vaccine and placebo recipients, determined risk factors for HIV acquisition, and examined the role of insertive anal intercourse in HIV risk among uncircumcised men. RESULTS: Few sexual risk behaviors were significantly higher in vaccine versus placebo recipients at baseline or during follow-up. Among uncircumcised men, vaccine recipients at baseline were more likely to report unprotected insertive anal intercourse with HIV-negative partners (24.9% vs. 18.1%; P = 0.03). Among uncircumcised men who had prior Ad5 immunity, vaccine recipients were more likely to report unprotected insertive anal intercourse with partners of unknown HIV status (46.0% vs. 37.8%; P = 0.05). Vaccine recipients remained at higher risk of HIV infection compared with placebo recipients (hazard ratio = 2.8; 95% confidence interval, 1.2-6.8) controlling for potential confounders. CONCLUSIONS: These analyses do not support a behavioral explanation for the increased HIV infection rates observed among uncircumcised men in the Step Study. Identifying biologic mechanisms to explain the increased risk is a priority .
Authors: Katherine Masek-Hammerman; Hualin Li; Jinyan Liu; Peter Abbink; Annalena La Porte; Kara L O'Brien; James B Whitney; Angela Carville; Keith G Mansfield; Dan H Barouch Journal: J Virol Date: 2010-08-04 Impact factor: 5.103
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Adel Benlahrech; Julian Harris; Andrea Meiser; Timos Papagatsias; Julia Hornig; Peter Hayes; Andre Lieber; Takis Athanasopoulos; Veronique Bachy; Eszter Csomor; Rod Daniels; Kerry Fisher; Frances Gotch; Len Seymour; Karen Logan; Romina Barbagallo; Linda Klavinskis; George Dickson; Steven Patterson Journal: Proc Natl Acad Sci U S A Date: 2009-11-16 Impact factor: 11.205
Authors: Natalie A Hutnick; Diane G Carnathan; Sheri A Dubey; George Makedonas; Kara S Cox; Lisa Kierstead; Sarah J Ratcliffe; Michael N Robertson; Danilo R Casimiro; Hildegund C J Ertl; Michael R Betts Journal: Nat Med Date: 2009-07-20 Impact factor: 53.440
Authors: Richard M Novak; Barbara Metch; Susan Buchbinder; Robinson Cabello; Yeycy Donastorg; John-Peter Figoroa; Hend Abdul-Jauwad; Hend Adbul-Jauwad; Patrice Joseph; Ellen Koenig; David Metzger; Magda Sobieszycz; Mark Tyndall; Carmen Zorilla Journal: AIDS Date: 2013-07-17 Impact factor: 4.177
Authors: Elizabeth S Gabitzsch; Joseph P Balint-Junior; Younong Xu; Stephanie Balcaitis; Brigitte Sanders-Beer; Julie Karl; Kent J Weinhold; Slobodan Paessler; Frank R Jones Journal: Vaccine Date: 2012-10-02 Impact factor: 3.641
Authors: G E Gray; B Metch; G Churchyard; K Mlisana; M Nchabeleng; M Allen; Z Moodie; J Kublin; L-G Bekker Journal: Vaccine Date: 2013-01-29 Impact factor: 3.641